Optimi psilocybin capsules included in Medibank program

Mr. Dane Stevens reports OPTIMI HEALTH'S PSILOCYBIN CAPSULES SELECTED FOR MEDIBANK INSURANCE PROGRAM Optimi Health Corp.'s five-milligram naturally derived psilocybin capsules have been selected for inclusion in Medibank's psychotherapy program, a $10-million (Australian) insurance-backed initiative that has been expanded to cover treatment-resistant depression. Medibank, Australia's largest private health insurer with approximately 4.2 million customers, has expanded its psychotherapy program to reimburse psilocybin-assisted therapy for patients with TRD, following its earlier funding of an MDMA-assisted therapy for posttraumatic stress disorder. For this program, Emyria Ltd., through its wholly owned Empax Centre located in Perth, Western Australia, is responsible for delivery of clinical services, and selected Optimi's psilocybin capsules for inclusion in the program through Optimi's exclusive distributor Mind Medicine Australia. The Medibank psychotherapy program funding forms part of a broader $50-million (Australian) initiative by the insurer, committed over five years to improving mental health access, innovation and prevention -- reinforcing its strategic shift to support novel therapies such as psilocybin and MDMA. Optimi previously announced that its psilocybin capsules became available in Australia on Sept. 3, 2025, under the authorized prescriber scheme. Dane Stevens, chief executive officer of Optimi, said: "The inclusion of our psilocybin capsules in Medibank's insurance-backed program for treatment-resistant depression reflects the growing role of standardized psychedelic medicines in insured mental health care. This development helps ensure Medibank's patients will gain access to therapies that were previously out of financial reach and marks an important step towards Optimi's integration into insurance-backed regulated care." About Optimi Health Corp. Optimi Health is a Canadian good-manufacturing-practice-compliant pharmaceutical drug manufacturer licensed by Health Canada for the handling of controlled substances and GMP production. From two 10,000-square-foot facilities in British Columbia and operating under a drug establishment licence from Health Canada, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia through the authorized prescriber scheme and accessible in Canada through the special access program. We seek Safe Harbor.